跳至主要内容
临床试验/NCT04040296
NCT04040296已完成不适用

Personalized Recommendations for Acute Kidney Injury (AKI) Care Using a Kidney Action Team: A Randomized Trial

Yale University2 个研究点 分布在 1 个国家目标入组 4,003 人开始时间: 2021年10月29日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
4,003
试验地点
2
主要终点
Composite Outcome Showing the Percentage of Participants With Any One of the Following: Progression of AKI, Inpatient Dialysis, or Inpatient Death

研究概览

简要总结

This is a randomized clinical trial of a "Kidney Action Team", which will provide timely, personalized recommendations for the diagnosis and initial treatment of hospitalized patients with Acute Kidney Injury (AKI).

详细描述

Acute Kidney Injury (AKI), defined as an abrupt loss in kidney function, is common, occurring in 5-20% of hospitalized patients, and carries a significant and independent risk of inpatient mortality. International guidelines for the treatment of AKI focus on "best practices" that include appropriate management of drug dosing, the avoidance of kidney-toxic exposures, and careful assessment of fluid and electrolyte balance. Early nephrologist involvement may also improve outcomes in AKI. However, AKI, which is often asymptomatic, is frequently overlooked in a variety of hospital settings and many "best practices" occur infrequently and inconsistently.

The investigators previously conducted a randomized clinical trial testing the efficacy of electronic alerts for AKI, randomizing patients with AKI to usual care, or to an alert group in which a single alert was sent to the patient's primary provider. The study demonstrated clinical equipoise regarding the effectiveness of such alerting, as there was no improvement in the rates of AKI progression, dialysis or mortality among those in the alert group.

Rather than simply making providers aware of AKI, it may be beneficial to provide them with actionable items to increase recognition and rate of best practices. Further, because of the heterogeneous nature of AKI, personalized recommendations tailored to individual patients that are delivered directly to the patient care team may improve AKI outcomes. The aim of this study is to determine, through a single-blind, parallel group, randomized controlled multicenter clinical trial, if personalized recommendations, as delivered by a Kidney Action Team, for the work-up and treatment of AKI will improve patient outcomes. The Kidney Action team will serve as a centralized, remote monitoring service and will consist of a group of highly trained individuals, including an advanced practitioner, a pharmacist and a board-certified nephrologist, dedicated to reviewing enrolled patient's charts and providing recommendations for patient diagnosis and initial work up and care within 60 minutes of AKI onset. Recommendations will span five domains of care, including diagnostic workup, acid/base management, electrolyte management, hemodynamic management, and medication management.

Using the Kidney Disease: Improve Global Outcomes creatinine criteria, inpatients in sites of the Yale New Haven Health System and of the John Hopkins University Health System who develop AKI during the course of their hospitalization will be randomized to either receive usual care, or to an active intervention group in which the recommendations of the Kidney Action Team are delivered to the patient's primary care team in the form of a structured note in the electronic health record to be cosigned by the attending of record. The primary clinical outcome will be a composite of AKI progression, dialysis and death at 14 days post-randomization. The primary process outcome will be the percent of recommendations made that are enacted within 24 hours after randomization.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults ≥ 18 years admitted to a participating hospital (six hospitals in the Yale New Haven Health system and two hospitals of the John Hopkins University Health system)
  • Stage 1 Acute Kidney Injury as defined by KDIGO creatinine criteria:
  • 0.3 mg/dl increase in inpatient serum creatine over 48 hours OR
  • 50% relative increase in inpatient serum creatinine over 168 hours

排除标准

  • Admission to hospice service or comfort measures only order
  • Recipient of a solid organ transplant
  • Immediate dialytic indication determined by the following:
  • serum K >/= 7
  • arterial pH < 7.15
  • BUN > 150 mg/dL
  • acute ingestion of dialyzable toxins
  • refractory volume overload
  • Patients who meet any of these critical values will not be enrolled in the trial and the Kidney Action Team will directly notify the treating team.
  • Pre-existing CKD stage V or End Stage Kidney Disease
  • Initial hospital creatinine > 4.0 mg/dl
  • Patients who have been seen by nephrology or already have a nephrology consult
  • Status post-nephrectomy (partial or radical) during index admission

结局指标

主要结局

Composite Outcome Showing the Percentage of Participants With Any One of the Following: Progression of AKI, Inpatient Dialysis, or Inpatient Death

时间窗: 14 days post randomization or at hospital discharge, whichever comes first

Progression of AKI is defined by an increase in KDIGO creatinine stage from that present at the time of randomization. Dialysis is defined by the receipt of hemodialysis, continuous renal replacement therapy or peritoneal dialysis. Isolated ultrafiltration treatments (for the purpose of volume removal) will not be included. Mortality will be determined from hospital administrative records. The rates of the primary outcome will be compared between the study arms using the Cochrane-Mantel-Haenszel chi-square test, accounting for stratification by hospital.

次要结局

  • Percentage of Recommendations Implemented by the Primary Care Team(24 hours after randomization)
  • Percentage of Patients With Progression of Acute Kidney Injury(Assessed from time of randomization to time of AKI progression (within 14 days post randomization))
  • Percentage of Patients Who Receive Inpatient Dialysis(Assessed from time of randomization to time of receipt of inpatient dialysis (within 14 days post randomization))
  • Percentage of Inpatient Mortality(Assessed from time of randomization to date of death from any cause, within 14 days of randomization)
  • Percent of Patients Who Receive a Kidney Consult Within 14 Days(Assessed from the time of randomization to time of first kidney consult (within 14 days post-randomization))
  • Percent of Patients Who Are Discharged to Hospice Care 14 Days(Assessed from the time of randomization to time discharge to hospice (within 14 days post-randomization))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验